Updates in Management of Gastrointestinal Malignancies

Friday, May 10, 2024, 7:00 AM - 3:30 PM, A1-22 Auditorium. Elmhurst Hospital, Elmhurst, NY


This symposium focuses on updates in diagnosis and multidisciplinary management of selected gastrointestinal and hepatopancreatic cancers and precancerous conditions. Latest technological and scientific advancements and clinical guidelines in prevention, diagnosis and treatment will be discussed.

1. Describe the management of the pancreatic cysts and innovative endoscopic techniques that are utilized.
2. Explain the management of locally advanced pancreatic cancer
3. Assess new therapeutic approaches in management of cholangiocarcinoma
4. Review the most recent guidelines in management of neuroendocrine tumors of liver, pancreas, and GI tract
5. Discuss screening, surveillance and surgical management of hereditary colon cancer
6. Review new treatment approaches in rectal cancer

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (5.25 hours), Non-Physician Attendance (5.25 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose all their financial relationships with ineligible companies within the prior 24 months. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material. Relevant financial relationships will be mitigated and disclosed to learners before the activity takes place.